Predicting drug-drug interactions involving multiple mechanisms using physiologically based pharmacokinetic modeling: A case study with ruxolitinib

Clinical Pharmacology and Therapeutics

Volumn 97, Issue 2, 2015, Pages 177-185

  Shi, J G ^a   Fraczkiewicz, G ^b   Williams, W V ^a   Yeleswaram, S ^a  

^a Experimental Station   (United States)

^b Simulations Plus Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; ERYTHROMYCIN; FLUCONAZOLE; KETOCONAZOLE; RIFAMPICIN; RUXOLITINIB; CYTOCHROME P450 3A INDUCER; CYTOCHROME P450 3A INHIBITOR; PYRAZOLE DERIVATIVE;

ADULT; AREA UNDER THE CURVE RATIO; ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; FIRST PASS EFFECT; GLOMERULUS FILTRATION; HUMAN; KIDNEY CLEARANCE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; BIOLOGICAL MODEL; DIET RESTRICTION; DRUG INTERACTION;

CYTOCHROME P-450 CYP3A INDUCERS; CYTOCHROME P-450 CYP3A INHIBITORS; DIGOXIN; DRUG INTERACTIONS; ERYTHROMYCIN; FASTING; FLUCONAZOLE; HUMANS; KETOCONAZOLE; MODELS, BIOLOGICAL; PROSPECTIVE STUDIES; PYRAZOLES; RETROSPECTIVE STUDIES; RIFAMPIN;

EID: 84927172074     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.30     Document Type: Article

References (28)

1. Zhang, L., Reynolds, K.S., Zhao, P. & Huang, S.M. Drug interactions evaluation: An integrated part of risk assessment of therapeutics. Toxicol. Appl. Pharmacol. 243, 134-145 (2010).
2. US Food and Drug Administration. Draft guidance for industry: Drug interaction studies - study design, data analysis, and implications for dosing and labeling (2012). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf
3. European Medicines Agency. Guideline on the investigation of drug interactions (2012).http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2012/07/WC500129606.pdf>
4. Vieira, M.L. et al. Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug. Clin. Pharmacol. Ther. 95, 189-198 (2014).
5. Greenblatt, D.J. In vitro prediction of clinical drug interactions with CYP3A substrates: We are not there yet. Clin. Pharmacol. Ther. 95, 133-135 (2014).
6. Fahmi, O.A., Maurer, T.S., Kish, M., Cardenas, E., Boldt, S. & Nettleton, D. A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro. Drug Metab. Dispos. 36, 1698-1708 (2008).
7. Fahmi, O.A. et al. Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: Predictions of compounds as precipitants of interaction. Drug Metab. Dispos. 37, 1658-1666 (2009).
8. Einolf, H.J. Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica 37, 1257-1294 (2007).
9. Guest, E.J., Rowland-Yeo, K., Rostami-Hodjegan, A., Tucker, G.T., Houston, J.B. & Galetin, A. Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: Comparison of dynamic and statistic models. Br. J. Clin. Pharmacol. 71, 72-87 (2010).
10. Shi, J.G. et al. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J. Clin. Pharmacol. 52, 809-818 (2012).
11. Shilling A.D. et al. Metabolism, excretion and pharmacokinetics following an oral dose of 14C-INCB018424 to healthy human subjects. Drug Metab. Dispos. 38, 2023-2031 (2010).
12. Shi, J.G. et al. The pharmacokinetics, pharmacodynamics and safety of orally dosed INCB018424 phosphate in healthy volunteers. J. Clin. Pharmacol. 51, 1644-1654 (2011).
13. Chen, X., Williams, W.V., Sandor, V., & Yeleswaram, S. Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or postessential thrombocythemia myelofibrosis (PET MF). J. Clin. Pharmacol. 53, 721-730 (2013).
14. Huffman, D.H. & Azarnoff, D.L. Absorption of orally given digoxin preparations. J. Am. Med. Assoc. 222, 957-960 (1972).
15. Baneyx, G., Parrot N., Meille, C., Iliadis, A. & Lave T. Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: Influence of time between substrate and inducer administration. Eur. J. Pharm. Sci. 56C, 1-15 (2014).
16. Fluconazole (Diflucan) [U.S. prescribing information]. http://www.accessdata.fda.gov/drugsat.fda-docs/label/2011/019949s051lbl.
17. Gupta, P. et al. Evaluation of the effect of fluconazole and ketoconazole on the pharmacokinetics of tofacitinib in healthy adult subjects. Clin. Pharmacol. Drug Dev. 3, 72-77 (2013).
18. Shi, J.G., Zhang, Y. & Yeleswaram, S. The relevance of assessment of intestinal P-gp inhibition using digoxin as an in vivo probe substrate. Nat. Rev. Drug Discov. 9, 215-236 (2010).
19. Eberl, S. et al. Role of p-glycoprotein inhibition for drug interactions: Evidence from in vitro and pharmacoepidemiological studies. Clin. Pharmacokinet. 46, 1039-1049 (2007).
20. Tsutsumi, K. et al. The effect of erythromycin and clarithromycin on the pharmacokinetics of intravenous digoxin in healthy volunteers. J. Clin. Pharmacol. 42, 1159-1164 (2002).
21. Zhao, P. et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin. Pharmacol. Ther. 89, 259-267 (2011).
22. Huang, S.-M. & Rowland, M. The role of physiologically based pharmacokinetic modeling in regulatory review. Clin. Pharmacol. Ther. 91, 542-549 (2012).
23. Zhao, P., Rowland, M. & Huang, S.-M. Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin. Pharmacol. Ther. 92, 17-20 (2012).
24. International Programme on Chemical Safety (IPCS), 2010. Characterization and application of physiologically based pharmacokinetic models in risk assessment, World Health Organization, International Programme on Chemical Safety, Geneva, Switzerland. http://www. who.int/ipcs/methods/harmonization/areas/pbpk-models.pdf (2010).
25. Tsamandouras, N., Rostami-Hodjegan, A. & Aarons, L. Aarons. Combining the "bottom-up" and "top-down" approaches in pharmacokinetic modeling: Fitting PBPK models to observed clinical data. Br. J. Clin. Pharmacol. (in press).
26. Agoram, B., Woltosz, W.S. & Bolger, W.S. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv. Drug Deliv. Rev. 50 (suppl. 1), S41-S67.
27. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. & Guengerich, F.P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-423 (1994).
28. Guengerich, F.P. Cytochrome P-450 3A4: Regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 39, 1-17 (1999).